Kaiqin She
Overview
Explore the profile of Kaiqin She including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
92
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jiang A, Liang L, She K, Lu F
Front Med (Lausanne)
. 2024 Sep;
11:1369884.
PMID: 39267980
Background: Multiple pigmented epithelial cysts at the edge of pupils, that is, iris flocculi, in both eyes, are rare ocular diseases. It has been demonstrated that this disease can be...
2.
Tao Z, Bu S, Liang L, Yang Y, She K, Lu F
Transl Vis Sci Technol
. 2023 Dec;
12(12):7.
PMID: 38054929
Purpose: To assess the quantitative differences in vessel density and retinal thickness of X-linked retinoschisis (XLRS) patients and RS1 mutation carriers, and the correlation with best-corrected visual acuity (BCVA) with...
3.
Tao Z, Liu W, Chen Q, Zhang L, She K, Zhao G, et al.
Invest Ophthalmol Vis Sci
. 2023 Jul;
64(10):30.
PMID: 37486293
Purpose: To explore the role of Th2 signaling pathway in allergic conjunctivitis (AC). Methods: Serum Th2 cytokines IL-4 or IL-13 of patients with AC were detected using the Meso scale...
4.
Li R, Jing Q, She K, Wang Q, Jin X, Zhao Q, et al.
Hum Gene Ther
. 2023 May;
34(13-14):616-628.
PMID: 37227014
Adeno-associated virus (AAV)-based gene therapy has been shown to be safe and effective in numerous animal models and clinical trials for various ophthalmic diseases. Stargardt disease (STGD1; MIM #248200) is...
5.
Su J, She K, Song L, Jin X, Li R, Zhao Q, et al.
Mol Ther Nucleic Acids
. 2023 Mar;
31:596-609.
PMID: 36910709
Retinitis pigmentosa (RP) is a group of retinal diseases that cause the progressive death of retinal photoreceptor cells and eventually blindness. Mutations in the β-domain of the phosphodiesterase 6 ()...
6.
Su J, Jin X, She K, Liu Y, Song L, Zhao Q, et al.
Mol Biomed
. 2023 Feb;
4(1):6.
PMID: 36813914
Mucopolysaccharidosis type I (MPS I) is a severe disease caused by loss-of-function mutation variants in the α-L-iduronidase (Idua) gene. In vivo genome editing represents a promising strategy to correct Idua...
7.
She K, Liu Y, Zhao Q, Jin X, Yang Y, Su J, et al.
Signal Transduct Target Ther
. 2023 Feb;
8(1):57.
PMID: 36740702
The prime editor (PE) can edit genomes with almost any intended changes, including all 12 possible types of base substitutions, small insertions and deletions, and their combinations, without the requirement...
8.
Li R, Wang Q, She K, Lu F, Yang Y
Mol Biomed
. 2022 Oct;
3(1):31.
PMID: 36239875
The discovery and development of the CRISPR/Cas system is a milestone in precise medicine. CRISPR/Cas nucleases, base-editing (BE) and prime-editing (PE) are three genome editing technologies derived from CRISPR/Cas. In...
9.
Jin X, Su J, Zhao Q, Li R, Xiao J, Zhong X, et al.
Mol Ther Methods Clin Dev
. 2022 May;
25:370-381.
PMID: 35573046
Mucopolysaccharidosis type I-Hurler (MPS I-H) is a neurodegenerative lysosomal storage disorder (LSD) caused by inherited defects of the α-L-iduronidase () gene. Current treatments are ineffective for treating central nervous system...
10.
She K, Su J, Wang Q, Liu Y, Zhong X, Jin X, et al.
Mol Ther Methods Clin Dev
. 2022 Feb;
24:210-221.
PMID: 35141350
Inhibition of vascular endothelial growth factor (VEGF) is the standard therapy for neovascular age-related macular degeneration (nAMD). However, anti-VEGF agents used in the clinic require repeated injections, causing adverse effects....